162 related articles for article (PubMed ID: 30419308)
1. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
Spiegel DY; Hong JC; Oyekunle T; Waters L; Lee WR; Salama JK; Koontz BF
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):834-842. PubMed ID: 30419308
[TBL] [Abstract][Full Text] [Related]
2. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Kishan AU; Wang X; Sun Y; Romero T; Michalski JM; Ma TM; Feng FY; Sandler HM; Bolla M; Maingon P; De Reijke T; Neven A; Steigler A; Denham JW; Joseph D; Nabid A; Carrier N; Souhami L; Sydes MR; Dearnaley DP; Syndikus I; Tree AC; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Efstathiou JA; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Xiang M; Rettig MB; Reiter RE; Zaorsky NG; Ong WL; Dess RT; Steinberg ML; Nickols NG; Roy S; Garcia JA; Spratt DE;
Eur Urol; 2022 Jul; 82(1):106-114. PubMed ID: 35469702
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
Arai M; Kosaka T; Yasumizu Y; Takeda T; Matsumoto K; Oya M
Int J Urol; 2023 Feb; 30(2):235-239. PubMed ID: 36375076
[TBL] [Abstract][Full Text] [Related]
4. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
[TBL] [Abstract][Full Text] [Related]
5. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
6. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
7. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy.
Son CH; Hamstra DA; Feng FY; Liauw SL
Am J Clin Oncol; 2017 Aug; 40(4):348-352. PubMed ID: 25436827
[TBL] [Abstract][Full Text] [Related]
8. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
9. Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer.
Kohutek ZA; Weg ES; Pei X; Shi W; Zhang Z; Kollmeier MA; Zelefsky MJ
Urology; 2016 Jan; 87():146-52. PubMed ID: 26476405
[TBL] [Abstract][Full Text] [Related]
10. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer.
Roy S; Grimes S; Eapen L; Spratt DE; Malone J; Craig J; Morgan SC; Malone S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1179-1188. PubMed ID: 32565318
[TBL] [Abstract][Full Text] [Related]
12. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.
Stoyanova R; Pahlajani NH; Egleston BL; Buyyounouski MK; Chen DY; Horwitz EM; Pollack A
Cancer; 2013 Mar; 119(5):1080-8. PubMed ID: 23096533
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
[TBL] [Abstract][Full Text] [Related]
14. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
[TBL] [Abstract][Full Text] [Related]
16. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
[TBL] [Abstract][Full Text] [Related]
17. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
20. Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT.
Hutten R; Tward JD
Clin Genitourin Cancer; 2022 Jun; 20(3):e263-e269. PubMed ID: 35304077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
